Open AccessAbstract CT213: Impact of smoking on outcomes with durvalumab following chemoradiotherapy in unresectable Stage III NSCLC (PACIFIC)
Author(s) -
David Planchard,
Mustafa Özgüroğlu,
Davey B. Daniel,
Augusto Villegas,
David Vicente,
Shuji Murakami,
Rina Hui,
Corinne Faivre–Finn,
Luis PazAres,
YiLong Wu,
Euan Macpherson,
Michael Newton,
Phillip A. Dennis,
Scott Antonia
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct213
Subject(s) - medicine , durvalumab , pneumonitis , chemoradiotherapy , hazard ratio , incidence (geometry) , stage (stratigraphy) , placebo , radiation therapy , oncology , cancer , confidence interval , lung , pembrolizumab , pathology , paleontology , physics , alternative medicine , immunotherapy , optics , biology